Data from FDA (Food and Drug Administration, USA) - Curated by EPG Health - Last updated 04 September 2018


ROTARIX is a vaccine indicated for the prevention of rotavirus gastroenteritis caused by G1 and non-G1 types (G3, G4, and G9). ROTARIX is approved for use in infants 6 weeks to 24 weeks of age. (1)

Full Prescribing information

Learning Zones

An Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.

Inflammatory Bowel Disease Knowledge Centre

Inflammatory Bowel Disease Knowledge Centre

The Inflammatory Bowel Disease (IBD) Knowledge Centre contains key information relating to the epidemiology and pathophysiology of Crohn’s disease and ulcerative colitis, highlighting prevalence, impact and unmet needs and the underlying inflammatory processes that drive IBD, considering some of the key inflammatory pathways.

Inflammatory bowel disease assessment tools

Inflammatory bowel disease assessment tools

'New IBD assessment tools at a glance' - an educational symposium sponsored by Sandoz.

Fluid Management

Fluid Management

Are you up-to-date with the latest evidence of effective procedures for fluid management?

+ 2 more

Load more

Related Content

Advisory information


• A demonstrated history of hypersensitivity to the vaccine or any component of the vaccine. (4.1, 11)
• History of uncorrected congenital malformation of the gastrointestinal tract that would predispose the infant to intussusception. (4.2)
• History of intussusception. (4.3)
• History of Severe Combined Immunodeficiency Disease (SCID). (4.4, 6.2)

Special warnings and precautions

• The tip caps of the prefilled oral applicators of diluent contain natural rubber latex which may cause allergic reactions. (5.1)
• Administration of ROTARIX in infants suffering from acute diarrhea or vomiting should be delayed. Safety and effectiveness of ROTARIX in infants with chronic gastrointestinal disorders have not been evaluated. (5.2)
• Safety and effectiveness of ROTARIX in infants with known primary or secondary immunodeficiencies have not been established. (5.3)
• In a postmarketing study, cases of intussusception were observed in temporal association within 31 days following the first dose of ROTARIX, with a clustering of cases in the first 7 days. (5.5, 6.2)

Adverse reactions
Common (≥5%) solicited adverse events included fussiness/irritability, cough/runny nose, fever, loss of appetite, and vomiting. (6.1)

Usage information

Dosing and administration

• Each dose is 1 mL administered orally. (2.2)
• Administer first dose to infants beginning at 6 weeks of age. (2.2)
• Administer second dose after an interval of at least 4 weeks and prior to 24 weeks of age. (2.2)

More information

Category Value
Authorisation number BLA125265
Orphan designation No
Product NDC 58160-854
Date First Approved 13-01-2013
Marketing authorisation holder GlaxoSmithKline Biologicals